{"name":"Sydnexis, Inc.","slug":"sydnexis-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Metabolic","slug":"metabolic","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"SYD-101 0.01%","genericName":"SYD-101 0.01%","slug":"syd-101-0-01","indication":"Type 2 diabetes","status":"phase_3"}]},{"name":"Infectious Disease","slug":"infectious-disease","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"SYD-101 0.03%","genericName":"SYD-101 0.03%","slug":"syd-101-0-03","indication":"Fungal skin infections (specific indication under investigation in Phase 3)","status":"phase_3"}]}],"pipeline":[{"name":"SYD-101 0.01%","genericName":"SYD-101 0.01%","slug":"syd-101-0-01","phase":"phase_3","mechanism":"SYD-101 is a small molecule that targets the SGLT2 receptor.","indications":["Type 2 diabetes"],"catalyst":""},{"name":"SYD-101 0.03%","genericName":"SYD-101 0.03%","slug":"syd-101-0-03","phase":"phase_3","mechanism":"SYD-101 is a topical antifungal agent that disrupts fungal cell membrane integrity.","indications":["Fungal skin infections (specific indication under investigation in Phase 3)"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiygFBVV95cUxNN05mRC1hamtpbm1TMmd5dWxkYWRJaDBJMXlYZ2xqNzdCTlQwRzkwS0NMdE5SbURYU1V4cllUZzNhV1dHMmk3bzlJR2hNMlluMFZaLVd2TTlRQVRkN2RvUFJoZGZ6RktkYzJsQTVDUXZkR25FQnd4Y1ZOUmtZSXZVQkJ6R0ptQ19FUjI3dlV3R2NCQVdLYnE5X1J6QlF6ZU5OSlV1LXBia3E2V21HaGFBUS05R3dHTF9Sdks1eGhTNWZuLTgzVVF4SC1n?oc=5","date":"2025-11-21","type":"regulatory","source":"BioCentury","summary":"Sydnexis setback highlights FDA’s lack of transparency, concerns about shifting goalposts - BioCentury","headline":"Sydnexis setback highlights FDA’s lack of transparency, concerns about shifting goalposts","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiywFBVV95cUxNZG5WNHdxQWtoUzRJOVFPOEtXY1pkN0V5Um03YVNuVTJTUTdZaWllZGNvellIZ0p6Y1h4b3dfQmFGYWpLR0tDbjBIcTFvVkdkYmVqU1lfU1Q5a0xXN1pmWTY4S3Ezajh6UDZWdVgxLTlRN1JBZk84LWFjODhOUkM1d29WNE5UMUJXcUpuZ1B3bFdTa3RfY3NVVVI2cmlRRW5JQ1RPX3NObk9ZYzRNZUl3Z1pXUW9EM1B4SzF6TDVGZmhOSHplbG5wWlBrSQ?oc=5","date":"2025-11-05","type":"trial","source":"Eyes On Eyecare","summary":"Sydnexis reports phase 3 topline data on SYD-101 eye drop for pediatric myopia - Eyes On Eyecare","headline":"Sydnexis reports phase 3 topline data on SYD-101 eye drop for pediatric myopia","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipwFBVV95cUxNME5yRTNNODZqUTV5b2lVMDFIQkNIZGF2YWlRQ1YtZGFJWGlCTHRULXdDYVZoeUJVVF9pRnF1Y0Qtemp1c1NWbU9pYkZ2NV8tS1lCbFgzOEl4M3c3dWR3aVZNM241VWZiRW5XSURvYUpWUmNXaTFGN2tVcTVOcjBfS05jSTRaRU90Y3ZDT0pXak0tUXpSbllaSWtScWk1eV9oLXpmaFVFaw?oc=5","date":"2025-10-27","type":"regulatory","source":"Eyes On Eyecare","summary":"FDA rejects Sydnexis’ NDA for low-dose atropine drop - Eyes On Eyecare","headline":"FDA rejects Sydnexis’ NDA for low-dose atropine drop","sentiment":"negative"},{"url":"https://news.google.com/rss/articles/CBMiuwFBVV95cUxOM0tlSDBSSWFUbzFKakRfYmNmRzFpLTZ2c1lmUl81aVkwRkVGRlpaWDRRZ3pPX2NHYkpVcHJyS2NnWkdPblBhV1FUVThSUS05UU1aVjJiTXJMM1BUWlFRN3Zja1FDYzRpZmxMYW5kdEI0WW5BenkzZ3ItRWhoNWdnTVItUmJNVXhlUXVPZm84UTg0TmNMczVTLUdQcndIVUVmVTBWV3BzUEJaeXc1ZlZjSVBEOUpNTjhsa1Q0?oc=5","date":"2025-10-24","type":"regulatory","source":"Ophthalmology Times","summary":"FDA issues Complete Response Letter to Sydnexis for SYD-101 pediatric myopia treatment - Ophthalmology Times","headline":"FDA issues Complete Response Letter to Sydnexis for SYD-101 pediatric myopia treatment","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiU0FVX3lxTE9NYld6YlJvMW1wcWRZMndLaHdYbzRJdnkwMG8xTTNuaGNsYWFLZEN2ejlkcDF1RHlKRE9QWG5kWC0yQzdqaGs1TTBHbG9sZUh0THJB?oc=5","date":"2025-10-24","type":"regulatory","source":"FirstWord Pharma","summary":"FDA rebuffs approval of Sydnexis' paediatric myopia therapy - FirstWord Pharma","headline":"FDA rebuffs approval of Sydnexis' paediatric myopia therapy","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMigwFBVV95cUxOUjNrenVyRkNyRDU3UHowNzJoVGFlcTlmX2ZkUDhqcDRTS3ZBU1Z5eGdibERQOEdpMklteUZucU5zb2dvZWVBeHlZN0FVOWd2SnRyWnlqOUtURUtMOUx1UjEyMlhBVklHSVlpbVptaC1RYnRPdEZkQzJSYmJ2NnppYy1Rbw?oc=5","date":"2025-06-06","type":"pipeline","source":"Pharmaceutical Technology","summary":"EC authorises Sydnexis’ paediatric myopia treatment - Pharmaceutical Technology","headline":"EC authorises Sydnexis’ paediatric myopia treatment","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisAJBVV95cUxPSTFRNVIxSENhZ0dROWhJZXF4NFBnR3F6SGFIYnBBcTVmdGpZYV9LUEJvUVhoSWdIVUpxVEk2aDhGa3pfX0ZWczFqZ2dCQVhOM3NtcmlVS3pOWUNJTTJ4UW5JTWZEeDI2Z2x3djlKck1iYzNzTmR5b1NlbHBOS2hfakd6RnJLLWRSV3ZVN1k4TlRrRllkVmg4RHdhdkFMdDRHb1QxRlhDNTlFTE9qTWdBSUs1ek1OOGpZM040c19DMDR3VHlpVHhQNTM4N1VjOGg5Z2g5QTNPMUpJU1A5djQ5bHl2ZnNPdXhnRU9PNFRXdUh5NVNhaWtZNWdqYzZvYktmZTdZMEZSMldsZXoyVEo5bDBROUg4U3d1ODZTcU8tZy11dkVmVk15ekNUUEpLVUVC?oc=5","date":"2025-06-05","type":"regulatory","source":"businesswire.com","summary":"Sydnexis Announces European Commission Approval of SYD-101, the First and Only Pharmaceutical Treatment for Slowing the Progression of Pediatric Myopia - businesswire.com","headline":"Sydnexis Announces European Commission Approval of SYD-101, the First and Only Pharmaceutical Treatment for Slowing the ","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMi9AFBVV95cUxNSkhWYnRNYmx5SndfQnZrRDFSOWlXSzVYS0VwMDRTNjlKT2pnWU9vaFJLaHM0UEdPQU5iMFJRM3IzZ0lFd1llOWdlcThsdk9fRFBnMVdtSGQ0T3lqWGp4Q0ZYeXpBU2w4ckRpQXRKRzRHZGZlcjgtYmxiOG05Z0ZwVWZHMVcybWVXR0Z1aDBOS1Jld21COVd4UHFuUTNTLTc2dFZISWF4Z1JnMU1nU29RU2VNQ0dUVkZkZkdrQ1BaU2lBYUNYQ0czME1Jc1JkZWViQnZZU1lzbHpHNVpiRERyazRqaS1lVXpNanc5QXJjdHNzMGJK?oc=5","date":"2025-06-05","type":"regulatory","source":"Ophthalmology Times Europe","summary":"European Commission approves low-dose atropine eye drop Ryjunea, Santen announces - Ophthalmology Times Europe","headline":"European Commission approves low-dose atropine eye drop Ryjunea, Santen announces","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMi5wFBVV95cUxNYUtVdktyaWk0X2tFR2FKOWZmS1YyM1FhcFlLZ2lRTW1DT2JCY2lOUlo0XzB2QUpwUGhvbkpYZFlBY0ctQjlzdkRDU3pKQUxEQUQtVWlQbG9RdDFhUUU5ZEg1ZXpTNVNvbkNyaFpQamY0ZHJXak9tMnVzOHc0RElQbUQyYmV1VW9BZkNoM2VHNGRna244QUMzUjktZmEwUGVaWm0ycnZjMkFVcExfTDVHem1JbEhYTGNnN3dZbm9hZlE5WDhKOWlyQjlTZ2JXRDd3VnZEMGJzX05UMmRuRHExS0V1UUhwRE0?oc=5","date":"2025-03-26","type":"pipeline","source":"PR Newswire UK","summary":"VUITY Reports Strong Market Performance, Setting New Benchmark in Presbyopia Care | DelveInsight - PR Newswire UK","headline":"VUITY Reports Strong Market Performance, Setting New Benchmark in Presbyopia Care | DelveInsight","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiwJBVV95cUxPMHk0OHk3LWlfNXBMcXRqR1BWSmF1b1RpYVhOdTNlMENLdl9IZ3VJbDRabGhuZlJmRHRlM1gxV0pEa2hVUWtmY0FqWnRMME1veGVncWsxVVNGMmhpenptYTlHbngzNlJ5LUNPUk9NNjJGU2lZTy05S21ncFVCMTlVVEhfQjd5SVRqU1Nwb29yVDVkbVozajBpeTh1RWJ6ZDgtMElUQmhsOEpOVkNkZEhXUHNGVXBwc1lyRm9ZNUZOTjVKVjZ1NXJqR0Z1OEpqQlYtYWJKWFpKVTk2cFBvTURmejJvWW85UW9LdnA3alVNdXJ3U0F4Q0ZzakpZbURoZXQ3dkpPdzRDY3lUc28?oc=5","date":"2025-03-11","type":"regulatory","source":"businesswire.com","summary":"Sydnexis Announces FDA Acceptance of New Drug Application for SYD-101 for the Treatment of Progression of Pediatric Myopia - businesswire.com","headline":"Sydnexis Announces FDA Acceptance of New Drug Application for SYD-101 for the Treatment of Progression of Pediatric Myop","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2023-10-19","type":"trial","source":"PR Newswire","summary":"Myopia Market to Grow at a Substantial Growth Rate During the Study Period (2019-2032), Predicts DelveInsight | Leading Companies - Nevakar, Vyluma, Bausch & Lomb, Sydnexis, Ocumension, ORA, LENZ Ther","headline":"Myopia Market to Grow at a Substantial Growth Rate During the Study Period (2019-2032), Predicts DelveInsight | Leading ","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimgFBVV95cUxNdUwzUVZzNWQzMUdIMUtLTFNmVEgtX01GSnVDdnNtYXRFTy1JT2NqSnVLZmpzb1p5dFF4T3dLcjFPTlJGZnVnWElfSktNMzM5OE44WWVsa0xPdHQ2OGNMMWczMmZfU3p5YWNld0RTTl9kTlh4OWxXNmcxMFI1bVpKdFNtUkhTaS1YOWFtUGQyMndJdnBEYjN5b2ZR?oc=5","date":"2021-08-17","type":"pipeline","source":"Fierce Pharma","summary":"Sydnexis scoops $45M to treat short-sightedness in kids - Fierce Pharma","headline":"Sydnexis scoops $45M to treat short-sightedness in kids","sentiment":"neutral"}],"patents":[],"drugCount":2,"phaseCounts":{"phase_3":2},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}